Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA.
Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Mol Aspects Med. 2020 Dec;76:100858. doi: 10.1016/j.mam.2020.100858. Epub 2020 Apr 28.
NLRP1 is an inflammasome forming pattern recognition receptor (PRR). When activated by pathogen- and damage- associated molecular patterns (PAMPS/DAMPS), NLRP1 inflammasome formation leads to inflammation through the production of proinflammatory cytokines IL-18 and IL-1β. As with other inflammasome forming NLR family members, NLRP1 also regulates cell death processes, termed pyroptosis. The domain structure of NLRP1 differs between mice and humans, making it possible for the function of the inflammasome to differ between species and adds complexity to the study of this NLR family member. In humans, mutations in both coding and non-coding regions of the NLRP1 gene are linked to a variety of diseases. Likewise, interruption of NLRP1 inhibitors or changes in the prevalence of NLRP1 activators can also impact disease pathobiology. Adding to its complexity, the NLRP1 inflammasome plays a dichotomous role in human diseases, functioning to either attenuate or augment miscellaneous biological processes in a tissue specific manner. For example, NLRP1 plays a protective role in the gastrointestinal tract by modulating the microbiome composition; however, it augments neurological disorders, cardio-pulmonary diseases, and cancer through promoting inflammation. Thus, it is critical that the role of NLRP1 in each of these disease processes be robustly defined. In this review, we summarize the current research landscape to provide a better understanding of the mechanisms associated with NLRP1 function and dysfunction in human disease pathobiology. We propose that a better understanding of these mechanisms will ultimately result in improved insight into immune system dysfunction and therapeutic strategies targeting inflammasome function in multiple human diseases.
NLRP1 是一种炎症小体形成模式识别受体(PRR)。当被病原体和损伤相关分子模式(PAMPS/DAMPS)激活时,NLRP1 炎症小体的形成通过产生促炎细胞因子 IL-18 和 IL-1β 导致炎症。与其他炎症小体形成的 NLR 家族成员一样,NLRP1 也调节细胞死亡过程,称为细胞焦亡。NLRP1 的结构域结构在小鼠和人类之间存在差异,这使得炎症小体的功能在不同物种之间存在差异,并为该 NLR 家族成员的研究增加了复杂性。在人类中,NLRP1 基因的编码和非编码区域的突变都与多种疾病有关。同样,NLRP1 抑制剂的中断或 NLRP1 激活物的流行率的变化也会影响疾病的病理生物学。更为复杂的是,NLRP1 炎症小体在人类疾病中起着双重作用,以组织特异性的方式减弱或增强各种生物学过程。例如,NLRP1 通过调节微生物组组成在胃肠道中发挥保护作用;然而,它通过促进炎症增强神经紊乱、心肺疾病和癌症。因此,必须强有力地定义 NLRP1 在这些疾病过程中的作用。在这篇综述中,我们总结了当前的研究现状,以更好地理解与 NLRP1 在人类疾病病理生物学中的功能和功能障碍相关的机制。我们提出,更好地理解这些机制最终将导致对免疫系统功能障碍的深入了解,并为针对多种人类疾病炎症小体功能的治疗策略提供指导。